Updated:
Ipsen
Ipsen S.A. was founded in 1929. The Beaufour family has retained control through successive generations, with Anne Beaufour and the late Henri Beaufour listed...
Ipsen
Ipsen S.A. was founded in 1929. The Beaufour family has retained control through successive generations, with Anne Beaufour and the late Henri Beaufour listed among principal shareholders. The firm executes venture and early-stage investments in biotechnology. Confirmed holdings include full ownership of ImCheck Therapeutics, Albireo and Epizyme, plus a 7.4% position in Sutro Biopharma. Capital is deployed via Ipsen Ventures and direct acquisitions. Geographic reach covers France, the United States and Luxembourg. Ipsen operates from its headquarters in Boulogne-Billancourt and maintains additional facilities including the Dreux and L'Isle-sur-la-Sorgue manufacturing plants. The company sponsors the Fondation Ipsen and the Alasol Foundation. May 2025: Ipsen held its Annual General Meeting in Paris. Control rests with the Beaufour family through layered Luxembourg vehicles that also oversee private real-asset holdings such as Château Labégorce. This architecture separates listed pharmaceutical operations from family wealth management.
General information
Firm type
Corporate Investor
Year founded
1929
AUM
Undisclosed
Location
Region
Europe
Country
France
City
Boulogne-Billancourt
Corporate office
65 quai Georges Gorse, 92100 Boulogne-Billancourt, France
Principals
Anne Beaufour
Major shareholder
Antoine Flochel
Vice Chairman of Ipsen and Managing Director of Mayroy S.A.
Philippe Bonhomme
Partner at Hottinguer; representative of Beech Tree S.A. on Ipsen's board
Sector focus
Frequently asked questions
Who runs investment decisions at Ipsen?
Anne Beaufour and Antoine Flochel oversee the family's holdings through Mayroy S.A. and Beech Tree S.A.
Does Ipsen participate in fund commitments or only direct deals?
Ipsen executes direct acquisitions and maintains an internal venture program focused on biotechnology companies.
Where does the underlying wealth come from?
The Beaufour family built its position through ownership of Ipsen S.A. since the company's founding in 1929.
What investment stages does Ipsen typically target?
The firm targets early-stage seed and venture investments in biotechnology.
Does Ipsen maintain philanthropic structures, and how are they separated?
Ipsen supports the Fondation Ipsen for health and science projects and the Alasol Foundation for education; both operate under separate governance.
How is Ipsen related to Mayroy S.A. and Beech Tree S.A.?
Mayroy S.A. and Beech Tree S.A. are Luxembourg holding companies through which the Beaufour family exercises control over Ipsen S.A.
Which sectors does Ipsen explicitly avoid?
No explicit avoidance sectors are stated in available records.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on registered investment advisers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: